Page last updated: 2024-08-16

risedronic acid and vitamin d 2

risedronic acid has been researched along with vitamin d 2 in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (25.00)	29.6817
2010's	3 (75.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Honda, Y; Iwamoto, J; Sato, Y	2
Kõks, S; Laius, O; Maasalu, K; Märtson, A	1

Reviews

1 review(s) available for risedronic acid and vitamin d 2

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Trials

2 trial(s) available for risedronic acid and vitamin d 2

Article	Year
Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease. Neurology, 2007, Mar-20, Volume: 68, Issue:12 Topics: Aged; Aged, 80 and over; Amino Acids; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Resorption; Double-Blind Method; Ergocalciferols; Etidronic Acid; Hip Fractures; Humans; Hyperparathyroidism; Male; Osteoporosis; Parkinson Disease; Placebo Effect; Prospective Studies; Risedronic Acid; Risk Assessment; Risk Factors; Treatment Outcome; Vitamin D Deficiency	2007
Once-weekly risedronate for prevention of hip fracture in women with Parkinson's disease: a randomised controlled trial. Journal of neurology, neurosurgery, and psychiatry, 2011, Volume: 82, Issue:12 Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Calcium; Drug Administration Schedule; Drug Therapy, Combination; Ergocalciferols; Etidronic Acid; Female; Hip Fractures; Humans; Parkinson Disease; Risedronic Acid	2011

Article

Year

Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease.

Neurology, 2007, Mar-20, Volume: 68, Issue:12

Topics: Aged; Aged, 80 and over; Amino Acids; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Resorption; Double-Blind Method; Ergocalciferols; Etidronic Acid; Hip Fractures; Humans; Hyperparathyroidism; Male; Osteoporosis; Parkinson Disease; Placebo Effect; Prospective Studies; Risedronic Acid; Risk Assessment; Risk Factors; Treatment Outcome; Vitamin D Deficiency

2007

Once-weekly risedronate for prevention of hip fracture in women with Parkinson's disease: a randomised controlled trial.

Journal of neurology, neurosurgery, and psychiatry, 2011, Volume: 82, Issue:12

Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Calcium; Drug Administration Schedule; Drug Therapy, Combination; Ergocalciferols; Etidronic Acid; Female; Hip Fractures; Humans; Parkinson Disease; Risedronic Acid

2011

Other Studies

1 other study(ies) available for risedronic acid and vitamin d 2

Article	Year
Use of drugs against osteoporosis in the Baltic countries during 2010-2014. Medicina (Kaunas, Lithuania), 2016, Volume: 52, Issue:5 Topics: Alendronate; Baltic States; Bone Density Conservation Agents; Calcium Channel Blockers; Denosumab; Diphosphonates; Drug Utilization; Ergocalciferols; Fractures, Bone; Humans; Ibandronic Acid; Osteoporosis; Risedronic Acid	2016